Tracers / [166Ho]Ho-166-PLLA
[166Ho]Ho-166-PLLA
Also written as Ho-166-PLLA
- Radionuclide
- Ho-166 t½ 1609.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 3
What it is
- Compound class
- Holmium-166 microspheres (poly-L-lactic acid, PLLA)
- Target / mechanism
- Selective internal radiotherapy (transarterial radioembolization) via microsphere embolization delivering beta radiation to liver tumors PMID 38564100
- Clinical application
- Selective internal radiotherapy (SIRT) of liver tumors/metastases, including combination with PRRT for neuroendocrine liver metastases PMID 40302310
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
Need this precursor?We can point you to suppliers for [166Ho]Ho-166-PLLA, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.